You are here
Disease modifying therapies
- Prof Feinstein discusses his research into cannabis on cognition in people with MS. The question he is investigating is: Does...
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up
Carrie M. Hersh, Thomas E. Love, Samuel Cohn, Claire Hara-Cleaver, Robert A. Bermel, Robert J. Fox, Jeffrey A. Cohen, Daniel Ontaneda
Multiple Sclerosis and Related Disorders, Volume 10, November 2016, Pages 44 - 52
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trialThe Lancet Neurology, Volume 15, Issue 11, October 2016, Pages 1148–1159
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis – Rationale and design
Francois Curtin, Herve Porchet, Robert Glanzman, Hans Martin Schneble, Virginie Vidal, Marie-Laure Audoli-Inthavong, Estelle Lambert, Hans Peter Hartung
Multiple Sclerosis and Related Disorders, Volume 9, September 2016, Pages 95-100
- PROTRACT is a multicentre retrospective real-world-evidence study ongoing in the United States and Canada. It is designed to show safety,...
- Dr Claire Riley and Dr Rebecca Farber summarize, that Progressive Multiple Sclerosis (MS) is an area lacking in treatment options...
- Journal of Neuroimmunology, Volume 298, 15 September 2016, Pages 24 - 31
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
Emer Fogarty, Susanne Schmitz, Niall Tubridy, Cathal Walsh, Michael Barry
Multiple Sclerosis and Related Disorders, September 2016, Pages 23 - 30
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials
Tobias Derfuss, Daniel Ontaneda, Jacqueline Nicholas, Xiangyi Meng, Kathleen Hawker
Multiple Sclerosis and Related Disorders, July 2016, Pages 124 - 130
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trialThe Lancet, Volume 388, Issue 10044, August 2016, Pages 576 - 585